Table 3.
Percentage of Subjects Who Achieved Target LDL-C and Changes in LDL-C from Baseline at Week 12 by Prior Hypertension Treatment and Hypertension Stage at Baseline
| LDL-C Stagea | Yes (N=698) | No (N=213) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Very High-Risk (N=484) | High-Risk (N=85) | Moderate-Risk (N=115) | Low-Risk (N=14) | Total (N=698) | Very High-Risk (N=41) | High-Risk (N=31) | Moderate-Risk (N=118) | Low-Risk (N=23) | Total (N=213) | |
| Number of subjects who achieved target LDL-C at Week 12b (%) | 126 (55.26) | 56 (91.80) | 58 (98.31) | 8 (100.00) | 248 (69.66) | 15 (62.50) | 18 (94.74) | 78 (97.50) | 19 (100.00) | 130 (91.55) |
| Changes in LDL-C (mg/dL) from baseline at Week 12 | ||||||||||
| n | 196 | 55 | 52 | 6 | 309 | 19 | 19 | 67 | 18 | 123 |
| Mean ± SD | −12.48± 20.82 | −10.57 ± 28.18 | −12.40 ± 32.58 | −32.67 ± 23.85 | −12.52 ± 24.64 | −44.15 ± 40.49 | −61.05 ± 36.22 | −64.20 ± 31.91 | −65.17 ± 36.05 | −60.76 ± 34.92 |
| 95% CIc | (−15.41, −9.55) | (−18.19, −2.96) | (−21.47, −3.33) | (−57.69, −7.64) | (−15.28, −9.76) | (−63.66, −24.63) | (−78.51, −43.60) | (−71.98, −56.42) | (−83.09, −47.24) | (−66.99, −54.52) |
| p-valued | <0.0001 | 0.0071 | 0.0168 | 0.0202 | <0.0001 | 0.0002 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| Percentage changes in LDL-C (%) from baseline at Week 12 | ||||||||||
| n | 196 | 55 | 52 | 6 | 309 | 19 | 19 | 67 | 18 | 123 |
| Mean ± SD | −11.64 ± 26.60 | −7.48 ± 28.48 | −5.87 ± 28.08 | −23.97 ± 13.38 | −10.17 ± 27.08 | −30.64 ± 29.92 | −44.28 ± 19.90 | −42.33 ± 17.13 | −41.96 ± 21.69 | −40.77 ± 20.84 |
| 95% CIc | (−15.39, −7.90) | (−15.18, 0.22) | (−13.69, 1.95) | (−38.01, −9.93) | (−13.20, −7.14) | (−45.06, −16.22) | (−53.87, −34.68) | (−46.51, −38.15) | (−52.74, −31.17) | (−44.49, −37.05) |
| p-valued | <0.0001 | 0.0567 | 0.1378 | 0.0071 | <0.0001 | 0.0008 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
Notes: aClassification according to the Korean Guidelines for the Management of Dyslipidemia IV: low-risk, one or fewer major risk factors (age, family history of premature CAD, hypertension, smoking, low levels of high-density lipoprotein cholesterol); moderate-risk, two or more major risk factors; high-risk, carotid disease (significant carotid artery stenosis), abdominal aortic aneurysm, or diabetes; very high-risk, CVD (CAD, peripheral artery disease, ischemic stroke, or transient ischemic attack). bTarget LDL-C: for very high-risk group, < 70 mg/dL; high-risk group, < 100 mg/dL; moderate-risk group, < 130 mg/dL; low-risk group < 160 mg/dL. c95% CI is a two-sided 95% confidence interval for the mean. dp-value using Wilcoxon signed-rank test or Paired t-test. Missing in LDL-C (hyperlipidemia treatment = “Yes”): - Baseline: Very high risk group (106 subjects), High risk group (9 subjects), Moderate risk group (24 subjects), Low risk group (5 subjects). - Week 12: Very high risk group (256 subjects), High risk group (24 subjects), Moderate risk group (56 subjects), Low risk group (6 subjects). Missing in LDL-C (hyperlipidemia treatment = “No”): - Baseline: Very high risk group (6 subjects), High risk group (1 subject), Moderate risk group (22 subjects), Low risk group (2 subjects). - Week 12: Very high risk group (17 subjects), High risk group (12 subjects), Moderate risk group (38 subjects), Low risk group (4 subjects).